Why did GAAP earnings decline while non-GAAP earnings grew strongly?

GAAP operating earnings fell 30% to $509 million, mainly because of a $184 million pre-tax goodwill impairment at the Navista & ION reporting unit, which management attributed to a higher discount rate reflecting changes in the risk profile of the business plans. Non-GAAP results exclude this impairment along with restructuring, acquisition-related amortization and compensation costs, and litigation items. The non-GAAP EPS increase was also boosted by a much lower non-GAAP tax rate (10.2% versus 22.4%), which management attributed to discrete planning benefits. Investors should weigh the GAAP figures and the tax-driven portion of the EPS growth when judging underlying performance.

What changed in the fiscal 2026 outlook?

Non-GAAP diluted EPS guidance was raised and narrowed to $10.70–$10.80, implying about 30–31% growth. Drivers include higher Pharmaceutical and Specialty Solutions segment profit growth (now 22–23%, up from 20–22%), higher Other segment profit growth (now 36–38%), a lower expected non-GAAP tax rate (about 19%, down from 21–23%), and a slightly lower share count (about 237 million). Interest and other expense guidance was increased to about $340 million from about $325 million, and adjusted free cash flow guidance was raised to $3.3–$3.7 billion. Cardinal Health does not provide GAAP guidance, citing the difficulty of forecasting excluded items.

How much of the EPS growth comes from the lower tax rate rather than operating performance?

The filing does not quantify this split. However, the non-GAAP tax rate dropped from 22.4% to 10.2% in the quarter, and management guides to about 19% for the full year, versus a prior range of 21–23%. Non-GAAP operating earnings grew 18%, while non-GAAP net earnings grew 32%, so the gap between those growth rates reflects the tax benefit and higher interest expense offset by a lower share count. Investors should treat the quarterly tax benefit as partly non-recurring, since it was described as resulting from discrete planning benefits.

What is driving weakness in the Global Medical Products and Distribution segment?

Segment revenue was flat at $3.1 billion, as lower distribution volumes were offset by growth in Cardinal Health brand products. Segment profit fell 36% to $25 million, primarily due to the adverse net impact of tariffs. Segment profit margin dropped to 0.79% from 1.23% a year earlier. The filing does not give a timeline for recovery, so investors should watch whether the company can offset tariff costs through pricing without losing customers to competitors that raise prices less.

How is the balance sheet and capital allocation positioned after this quarter?

Cardinal Health reduced leverage to 3.0x Adjusted Debt to EBITDA as of March 31, 2026, within its 2.75–3.25x target range, and maintained an investment-grade rating. It prepaid $100 million of its term loan ahead of schedule and completed an additional $250 million accelerated share repurchase, bringing fiscal 2026 repurchases to $1.0 billion. Total shareholders' deficit was $(2.7) billion at quarter end, which is consistent with its prior position. Investors should note that buybacks and dividends, along with a $340 million interest and other expense guide, must be funded from operating cash flow and debt capacity.

CAH 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Cardinal Health reported fiscal third-quarter 2026 results (quarter ended March 31, 2026) with revenue up 11% to $60.9 billion^a, driven mainly by brand and specialty pharmaceutical growth in its Pharmaceutical and Specialty Solutions segment.

GAAP diluted EPS fell 20% to $1.69^b and GAAP operating earnings fell 30% to $509 million, largely because of a $184 million pre-tax goodwill impairment at the Navista & ION reporting unit. On a non-GAAP basis, operating earnings rose 18% to $956 million and diluted EPS rose 35% to $3.17. The non-GAAP EPS gain was helped by a sharply lower non-GAAP tax rate of 10.2%, which management attributed to discrete planning benefits, and by a lower share count.

Management raised and narrowed fiscal 2026 non-GAAP diluted EPS guidance to $10.70^c–$10.80 (about 30–31% growth), from the prior range. The raise reflects stronger Pharmaceutical and Specialty Solutions and Other segment profit, a non-GAAP tax rate now expected near 19%, and fewer diluted shares (about 237 million). Partly offsetting these items, interest and other expense guidance was increased to about $340 million.

Adjusted free cash flow guidance was raised to $3.3^d–$3.7 billion. The company also cut leverage to 3.0x (within its 2.75–3.25x target), repaid $100 million of term loan early, and has repurchased $1.0 billion of shares year to date. For investors, the key questions are the quality of the EPS beat and the durability of segment profit.

The Global Medical Products and Distribution segment is weak, with profit down 36% on tariff impacts and flat revenue. GAAP results remain well below non-GAAP results because of recurring acquisition-related charges and impairments.

Year-to-date operating cash flow of $3.5 billion is well above last year's $0.9 billion, but that comparison is distorted by working-capital swings in accounts payable and inventory. Because the quarter's non-GAAP tax rate was unusually low, the full-year guidance raise depends partly on sustaining a roughly 19% tax rate.

02—Key points

Key Highlights

Revenue rose 11% year over year to $60.9 billion, led by the Pharmaceutical and Specialty Solutions segment ($56.1 billion, up 11%).
GAAP diluted EPS fell 20% to $1.69 and GAAP operating earnings fell 30% to $509 million, mainly due to a $184 million pre-tax goodwill impairment at Navista & ION.
Non-GAAP diluted EPS rose 35% to $3.17 and non-GAAP operating earnings rose 18% to $956 million; the non-GAAP effective tax rate fell to 10.2% from 22.4%, a significant contributor to EPS growth.
FY26 non-GAAP EPS guidance was raised and narrowed to $10.70–$10.80, with a non-GAAP tax rate now expected near 19% and interest and other expense raised to about $340 million.
Pharmaceutical and Specialty Solutions segment profit rose 18% to $784 million, while Global Medical Products and Distribution profit fell 36% to $25 million on tariff impacts.
Adjusted free cash flow guidance was raised to $3.3–$3.7 billion, and year-to-date operating cash flow was $3.5 billion versus $0.9 billion a year earlier.
Leverage was reduced to 3.0x (target 2.75–3.25x), $1.0 billion of share repurchases were completed year to date, and the company retained its investment-grade rating.

03—Questions

Frequently Asked Questions

Why did GAAP earnings decline while non-GAAP earnings grew strongly?
GAAP operating earnings fell 30% to $509 million, mainly because of a $184 million pre-tax goodwill impairment at the Navista & ION reporting unit, which management attributed to a higher discount rate reflecting changes in the risk profile of the business plans. Non-GAAP results exclude this impairment along with restructuring, acquisition-related amortization and compensation costs, and litigation items. The non-GAAP EPS increase was also boosted by a much lower non-GAAP tax rate (10.2% versus 22.4%), which management attributed to discrete planning benefits. Investors should weigh the GAAP figures and the tax-driven portion of the EPS growth when judging underlying performance.
What changed in the fiscal 2026 outlook?
Non-GAAP diluted EPS guidance was raised and narrowed to $10.70–$10.80, implying about 30–31% growth. Drivers include higher Pharmaceutical and Specialty Solutions segment profit growth (now 22–23%, up from 20–22%), higher Other segment profit growth (now 36–38%), a lower expected non-GAAP tax rate (about 19%, down from 21–23%), and a slightly lower share count (about 237 million). Interest and other expense guidance was increased to about $340 million from about $325 million, and adjusted free cash flow guidance was raised to $3.3–$3.7 billion. Cardinal Health does not provide GAAP guidance, citing the difficulty of forecasting excluded items.
How much of the EPS growth comes from the lower tax rate rather than operating performance?
The filing does not quantify this split. However, the non-GAAP tax rate dropped from 22.4% to 10.2% in the quarter, and management guides to about 19% for the full year, versus a prior range of 21–23%. Non-GAAP operating earnings grew 18%, while non-GAAP net earnings grew 32%, so the gap between those growth rates reflects the tax benefit and higher interest expense offset by a lower share count. Investors should treat the quarterly tax benefit as partly non-recurring, since it was described as resulting from discrete planning benefits.
What is driving weakness in the Global Medical Products and Distribution segment?
Segment revenue was flat at $3.1 billion, as lower distribution volumes were offset by growth in Cardinal Health brand products. Segment profit fell 36% to $25 million, primarily due to the adverse net impact of tariffs. Segment profit margin dropped to 0.79% from 1.23% a year earlier. The filing does not give a timeline for recovery, so investors should watch whether the company can offset tariff costs through pricing without losing customers to competitors that raise prices less.
How is the balance sheet and capital allocation positioned after this quarter?
Cardinal Health reduced leverage to 3.0x Adjusted Debt to EBITDA as of March 31, 2026, within its 2.75–3.25x target range, and maintained an investment-grade rating. It prepaid $100 million of its term loan ahead of schedule and completed an additional $250 million accelerated share repurchase, bringing fiscal 2026 repurchases to $1.0 billion. Total shareholders' deficit was $(2.7) billion at quarter end, which is consistent with its prior position. Investors should note that buybacks and dividends, along with a $340 million interest and other expense guide, must be funded from operating cash flow and debt capacity.

04—Continue

← View all 8-K filings